REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

Reprocell: Cardiomyocyte Maintenance Medium

cardiomyocytes medium (C) Reprocell 2009November 2009. Part of the QTempo series of qualified products for cardiomyocyte research. ReproCELL's cardiomyocyte maintanance medium  has been optimized and qualified for the maintanance of  cardiomyocytes. Cardiomyocytes maintained in ReproCELL's cardiomyocyte buffer can maintain spontaneous beat for wextended periods of time up to several months.
* Qualified for use with beating primate cardiomyocytes used in the QTempo system
 Cardiomyocyte maintenance Medium (100ml)    £40.00 (1 unit)

-->

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.

B. Kirschbaum, Merck Serono on stem cell research: Clear away complete confusion of terms

Dr Bernhard Kirschbaum (C) Wolf G Kroner 2009 February 2009. While many ethical questions surrounding the use of stem cells have been satisfactorily answered, a number of unresolved methodological and technical issues hamper applications in the pharmacceutical industry. Where are the stumbling blocks of today? What is Merck’s and Merck Serono’s approach, and with what prospects?



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 2 pages

Stem Cells: a discovery tool and a potential therapeutic modality

Dr Jonathan KnowlesSeptember 2009. What are the needs for stem cell technologies in the pharmaceutical industry? What are the major challenges, and how can you ensure a close fit with external collaborators, like I-STEM? An interview with Dr Jonathan Knowles, Member of the Roche Executive Committee and Head of Group Research.

 

 

 

Related Articles

Roche Ethiopia: Build-up of an emerging market

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

 


 



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 2 pages

Pfizer Regenerative Medicine: “It really started last year…”

Ruth McKernan (c) Pfizer Inc.Pfizer is rapidly expanding work on stem cell applications. A first hand account by Dr Ruth McKernan, the global CSO of Pfizer’s activities in the field, an evaluation of toxicity screening with embryonic stem cells and needs to move forward.

 

 

 

 

 



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 3 pages

Top 10 Tags

All Tags (2074)